THERAPY DOSSIER · th-c0f00f4b5665

TAT-fused NipR1 shielding peptide

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24398689 ↗2014Reported benefit

Lipopolysaccharide-induced lung injury involves the nitration-mediated activation of RhoA.

MouseEndotoxin/LPSC57BL/6Male

Model: Lipopolysaccharide-induced acute lung injury; human lung microvascular endothelial cells challenged with LPS in vitro

NipR1 attenuated RhoA nitration and barrier disruption in LPS-challenged human lung microvascular endothelial cells, and in mice it attenuated vessel leakage and inflammatory cell infiltration and preserved lung function.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…